Human Oncology & Pathogenesis Program

The Christopher Klebanoff Lab

Research

Christopher A. Klebanoff, MD
Assistant attending and member, IOS-HOPP, MSKCC

A form of cancer immunotherapy termed adoptive T cell transfer (ACT), in which a patient’s own T cells are engineered to recognize and attack cancer cells, can induce durable complete remissions in patients with advanced hematologic malignancies. By contrast, a similar approach has thus far failed to work in most patients with solid malignancies, the leading cause of adult cancer-related deaths. Two critical gaps in knowledge have limited the ability of ACT to be successfully applied to solid cancers: 1) understanding which antigens on the surface of cancer cells can be targeted by T cells that do not have the potential to cross- react with and injure normal tissues, and 2) insight into what factor(s) restrain the ability of transferred T cells to infiltrate, expand, and persist within a solid tumor mass. Using diverse techniques, including single-cell sequencing, biophysical measurements of T cell receptor (TCR) affinity, genetic engineering, and structural immunobiology, the Klebanoff laboratory seeks to address both factors currently limiting the application of ACT for advanced solid cancers.

Research Projects

The Christopher Klebanoff Lab

Publications

People

Christopher A. Klebanoff

Christopher A. Klebanoff, MD

Assistant attending and member, IOS-HOPP, MSKCC

  • Physician-scientist Christopher A. Klebanoff studies T cell immunobiology with an emphasis on adoptive T cell immunotherapy for the treatment of solid malignancies.
  • MD, Emory University School of Medicine
View physician profile
Physician profile

Members

Ilinca Aricescu
Ilinca Aricescu

GSK Graduate Student

Hannah Arkin
Hannah Arkin

Research Technician

Lauren B. Banks

Medical Oncology Fellow

Smita Chandran
Smita Chandran

Scientific Research Lead

Inaki Etxeberria
Inaki Etxeberria

Research Fellow

Christopher Bryce Johnson

Resident Physician Research Fellow

Korbinian Kropp
Korbinian Kropp

Research Associate

Fei Yi
Fei Yi

Research Fellow

Natalie Zimmerman
Natalie Zimmerman

Research Technician

Lab Alumni
Erica Brophy
Erica Brophy

Research Technician

Razan Eltilib
Razan Eltilib

Senior Research Technician

Matthew Femia
Matthew Femia

Research Technician

Si Ning “Leslie” Fu
Si Ning “Leslie” Fu

Research Assistant

Patricia Lopez

Senior Research Technician

Lab Affiliations

Achievements

  • NIH Fellows Award for Research Excellence (2013)
  • NCI/Center for Cancer Research Post Doctoral Research Fellow of the Year (2011)
  • AOA National Medical Honor Society (2006)
  • Howard Hughes Medical Institute continuing support scholarship (2004-2006)
  • Merk Index Award (2000)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Postdoctoral Fellows

Apply now

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Christopher A. Klebanoff discloses the following relationships and financial interests:

  • Achilles Therapeutics
    Provision of Services
  • Althea Biotherapeutics Inc
    Provision of Services
  • Bellicum
    Provision of Services
  • Bristol-Myers Squibb
    Ownership / Equity Interests
  • CVS Caremark Corp
    Ownership / Equity Interests
  • Gilead Pharmaceutical
    Ownership / Equity Interests
  • Johnson & Johnson
    Ownership / Equity Interests
  • Obsidian Therapeutics
    Provision of Services
  • T-Knife GmbH
    Provision of Services
  • United Health Group
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures